Navigation Links
Capella University Offers New MS in Psychology Specialization in Child and Adolescent Development : Capella is the only regionally accredited online university to offer this master's specialization
Date:10/29/2008

Capella University (www.capella.edu), an accredited(a) online university that has built its reputation by providing quality graduate education for working adults, has announced that it is offering a new Child and Adolescent Development specialization within its Master of Science in Psychology online degree program. Capella now offers the only master’s specialization in Child and Adolescent Development available from an online regionally accredited university.

MINNEAPOLIS (Business Wire EON) October 29, 2008 -- "There is a real need for professionals with special knowledge in child and adolescent development," said Dean Ginther, PhD, faculty chair in Capella's Harold Abel School of Psychology. "According to the Bureau of Labor Statistics, the individual and family services industry is expected to grow by 73 percent, making it one of the country's fastest growing industries. Child and adolescent development specialists not only bring critical skills to this fast-growing industry, but also to health care, government, and education programs focused on the needs of children and families. Our curriculum is designed to provide the knowledge, theory, and best practices necessary to support the development of children and adolescents, as well as advance our students' potential to become leaders in this important field of study."

The new MS in Psychology, Child and Adolescent Development specialization, leverages Capella's experience and faculty expertise in the field of mental health. The online university currently offers more than two dozen graduate specializations in counseling, psychology, and related fields.

Capella is now accepting enrollment applications for its MS in Psychology, Child and Adolescent Development specialization. For more information, please call 1-888-
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Capella University Launches Online PhD Specialization in Nursing Education
2. Capella University Launches PhD in Counselor Education and Supervision : The new degree program, one of few available online, addresses growing need for counseling faculty and supervisors
3. University of Iowa professor identifies new eating disorder
4. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
6. Tulane University to receive $14M for international HIV/AIDS program
7. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
8. Boston University School of Medicine researcher recipient of Memory Ride Grant
9. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
10. Medina General Hospital and University Hospitals Agree to Pursue Affiliation
11. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... Albany, NY (PRWEB) November 26, 2014 ... industry research requirements or email the details on sales(at)researchmoz(dot)us ... "Worldwide diabetes and drug discovery market 2014" with deep ... Diabetes is the result of high blood sugar. The ... is directly linked to the growing number of diabetics ...
(Date:11/26/2014)... 26, 2014 News Facts , ... capabilities at RSNA 2014 in Chicago. The company ... share diagnostic images, photos, videos and documents found ... #8107 will learn more about these innovative medical ... and partner initiatives – that enable more informed ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
(Date:11/26/2014)... -- Parents need to take an active role in ... Parents must make sure sports-playing teens have the ... chair of the American Migraine Foundation and a professor ... in Scottsdale, Ariz. in an American Migraine Foundation, said ... involved with teens sports needs to have appropriate training. ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... , MONDAY, May 21 (HealthDay News) -- The new blood ... blood clots in high-risk heart patients, a U.S. Food and ... briefing documents that were filed Monday in advance of an ... to vote on whether to recommend approval of Xarelto for ...
... HealthDay Reporter , MONDAY, May 21 (HealthDay News) -- ... helps overweight women lower the levels of certain hormones in ... breast cancer. The findings don,t ... Still, women who take medications to prevent the disease "need ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... be reducing their risk of psoriasis, Harvard University researchers report. ... scaly patches on the skin. Vigorous activity for ... risk by 25 percent to 30 percent, the researchers said. ...
... scientist from the Viral Immunology Center at Georgia State ... of the eye is associated with neovascular age-related macular ... elderly. The scientists found that human cytomegalovirus, a ... growth factor, or VEGF, a signal protein that regulates ...
... A team of scientists has developed a promising new ... shrink and die. The researchers hope that their discovery ... drug that effectively targets unhealthy, cancerous tissue without damaging ... be published in the Journal of Biological Chemistry ...
... went to John Edward Solder, a senior at Staples ... Interrogation of Prefrontal Cortex Dopamine D1 Receptor-Containing Neurons as ... Treat Prefrontal Disorders. The 18-year-old was able to specifically ... to activate dopamine neurons in the prefrontal cortex, a ...
Cached Medicine News:Health News:New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA 2Health News:Dieting May Lower Hormone Levels Tied to Breast Cancer 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 3Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:Strategy discovered to activate genes that suppress tumors and inhibit cancer 2Health News:Strategy discovered to activate genes that suppress tumors and inhibit cancer 3Health News:Optogenetics project takes top NIDA Addiction Science Award 2Health News:Optogenetics project takes top NIDA Addiction Science Award 3Health News:Optogenetics project takes top NIDA Addiction Science Award 4
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... DIEGO , Nov. 25, 2014 Halozyme Therapeutics, ... the Piper Jaffray Healthcare Conference in New York ... EDT/10:00 a.m. PDT . Dr. Helen Torley , ... The presentation will be webcast through the "Investors" ... a recording will be made available for 90 days following ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Delcath Systems, Inc. (Nasdaq: DCTH ) ... Senior Vice President of Medical Device Research and Development ... to the position of Vice President of Pharmaceutical Research ... based in the Company,s Queensbury, New York facility and ...
... Thomson Reuters, a global provider of information ... version of its award-winning Clinical Xpert Navigator ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO) (Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO) ... to access complete patient clinical data — ...
Cached Medicine Technology:Delcath Strengthens Research and Development Team with Key Appointments 2Delcath Strengthens Research and Development Team with Key Appointments 3Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 2Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: